Shilpa Johri

Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial

Marius M. Hoeper, Hikmet Al‐Hiti, Raymond L. Benza et al. · The Lancet Respiratory Medicine · 2021 · 161 citations

Medicine, Pharmacology, Pharmacotherapy +9

Inhaled treprostinil and forced vital capacity in patients with interstitial lung disease and associated pulmonary hypertension: a post-hoc analysis of the INCREASE study

Steven D. Nathan, Aaron B. Waxman, Sudarshan Rajagopal et al. · The Lancet Respiratory Medicine · 2021 · 141 citations

Medicine, Clinical Sciences, Pharmacotherapy +15

BREEZE: Open‐label clinical study to evaluate the safety and tolerability of treprostinil inhalation powder as Tyvaso DPI™ in patients with pulmonary arterial hypertension

Leslie Spikes, Abubakr Bajwa, Charles D. Burger et al. · Pulmonary Circulation · 2022 · 38 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Survival analysis from the INCREASE study in PH-ILD: evaluating the impact of treatment crossover on overall mortality

Steven D. Nathan, Shilpa Johri, Joanna M. Joly et al. · Thorax · 2023 · 23 citations · Full text

Medicine, Biostatistics, Pharmacotherapy +11

Bilateral Pneumothoraces After Unilateral Transthoracic Needle Biopsy of a Lung Nodule

Shilpa Johri, David Berlin, Abraham Sanders · CHEST Journal · 2003 · 15 citations

Medicine, Internal Medicine, Pathology +11